companydata.dkcompanydata.dk

Drug Development Consulting BidCo ApS: Financial statements 2025

CVR: 42287067

Source: annual report 2025, Danish Business Authority

01/01/2025 – 31/12/2025

Drug Development Consulting BidCo ApS (CVR 42287067) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK 5,875,000 and a net result of DKK -61,325,000 compared with DKK -13,215,000 the year before. That is an increase of 70.9% compared with the year before. Equity in the 2025 report amounted to DKK 32,493,000. The solvency ratio was 35.3%. The company had 2 employees in the financial year.

Gross Profit
DKK 5,875,000
Profit/Loss
DKK -61,325,000
Equity
DKK 32,493,000
Total Assets
DKK 92,013,000
Employees
2

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2025-5.9M-61.3M32.5M2
2024-3.4M-13.2M79M1
2023-2.3M-9.4M70.2M1
2022-3.8M-11.8M71.8M1

Official annual report

View the official annual report directly on the page with a Pro subscription.

How creditworthy is Drug Development Consulting BidCo ApS?

See the CDS score and get a full credit report with recommended credit limit and payment terms.

Read about the CDS score

Events in 2025

Drug Development Consulting BidCo ApS: The 2024 annual report is outMay 16, 2025

Drug Development Consulting BidCo ApS has published its annual report for 2024. Gross profit came to DKK 3,438,000, and the net result was DKK -13,215,000.

Rasmus Koch Nelund steps down as director of Drug Development Consulting BidCo ApSFeb 28, 2025

As of February 28, 2025, Rasmus Koch Nelund has stepped down as director of Drug Development Consulting BidCo ApS.

About Drug Development Consulting BidCo ApS

Drug Development Consulting BidCo ApS is a Danish company of the type Anpartsselskab based in Brøndby, founded in 2021. The company is registered under the industry Virksomhedsrådgivning og anden ledelsesrådgivning. The management consists of René Holmen Pedersen. The board consists of Niels Peder Nielsen (chair), Alejandra Maria Cristina Bonifacini Mørk, Rafael Natanek and Redmar Koene. The company is owned by Drug Development Consulting Holding ApS. The company has 1 employee (2026). In 2025, the company reported a gross profit of DKK 5,875,000 and a net result of DKK -61,325,000 compared with DKK -13,215,000 the year before. Equity in the 2025 report amounted to DKK 32,493,000.

Source: annual report 2025, Danish Business Authority

Other financial years